Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
Targeting cancer with antibody-drug conjugates: Promises and challenges
Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that
utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the …
utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the …
Killing by degradation: regulation of apoptosis by the ubiquitin-proteasome-system
R Abbas, S Larisch - Cells, 2021 - mdpi.com
Apoptosis is a cell suicide process that is essential for development, tissue homeostasis and
human health. Impaired apoptosis is associated with a variety of human diseases, including …
human health. Impaired apoptosis is associated with a variety of human diseases, including …
Chrysin mitigates diclofenac-induced hepatotoxicity by modulating oxidative stress, apoptosis, autophagy and endoplasmic reticulum stress in rats
Background Diclofenac (DF) is a non-steroidal anti-inflammatory drug (NSAID) generally
prescribed for the treatment of pain. In spite of the widespread use of DF, hepatotoxicity has …
prescribed for the treatment of pain. In spite of the widespread use of DF, hepatotoxicity has …
Programmed cell death, redox imbalance, and cancer therapeutics
X Dai, D Wang, J Zhang - Apoptosis, 2021 - Springer
Cancer cells are disordered by nature and thus featured by higher internal redox level than
healthy cells. Redox imbalance could trigger programmed cell death if exceeded a certain …
healthy cells. Redox imbalance could trigger programmed cell death if exceeded a certain …
Combining neratinib with CDK4/6, mTOR, and MEK inhibitors in models of HER2-positive cancer
M Zhao, S Scott, KW Evans, E Yuca, T Saridogan… - Clinical Cancer …, 2021 - AACR
Purpose: Neratinib is an irreversible, pan-HER tyrosine kinase inhibitor that is FDA
approved for HER2-overexpressing/amplified (HER2+) breast cancer. In this preclinical …
approved for HER2-overexpressing/amplified (HER2+) breast cancer. In this preclinical …
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines
Abstract Targeting BCL-X L via PROTACs is a promising strategy in reducing BCL-X L
inhibition associated platelet toxicity. Recently, we reported potent BCL-X L PROTAC …
inhibition associated platelet toxicity. Recently, we reported potent BCL-X L PROTAC …
Targeting Bcl-2 family proteins: what, where, when?
VV Senichkin, NV Pervushin, AP Zuev… - Biochemistry …, 2020 - Springer
Proteins of the Bcl-2 family are known as regulators of apoptosis, one of the most studied
forms of programmed cell death. The Bcl-2 protein family is represented by both pro-and …
forms of programmed cell death. The Bcl-2 protein family is represented by both pro-and …
[HTML][HTML] Clinicopathological Significance and Expression pattern of Bcl2 in Breast Cancer: A comprehensive in silico and in vitro Study
B-cell lymphoma/leukemia gene-2 (Bcl-2) is the primary proto-oncogene that has been
shown to work by preventing apoptosis/programmed cell death. Bcl-2 combines a variety of …
shown to work by preventing apoptosis/programmed cell death. Bcl-2 combines a variety of …
Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins
Introduction The anti-apoptotic BCL-2 family proteins, such as BCL-2, BCL-XL, and MCL-1,
are excellent cancer therapeutic targets. The FDA approval of BCL-2 selective inhibitor …
are excellent cancer therapeutic targets. The FDA approval of BCL-2 selective inhibitor …